Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

OBJECTIVES: Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the contact activation system. The study objective is to investigate the efficacy and safety of conestat alfa in improving dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Urwyler, Pascal, Charitos, Panteleimon, Moser, Stephan, Heijnen, Ingmar A. F. M., Trendelenburg, Marten, Thoma, Reto, Sumer, Johannes, Camacho-Ortiz, Adrián, Bacci, Marcelo R., Huber, Lars C., Stüssi-Helbling, Melina, Albrich, Werner C., Sendi, Parham, Osthoff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780206/
https://www.ncbi.nlm.nih.gov/pubmed/33397449
http://dx.doi.org/10.1186/s13063-020-04976-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780206/
https://www.ncbi.nlm.nih.gov/pubmed/33397449
http://dx.doi.org/10.1186/s13063-020-04976-x

Ejemplares similares